These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 27322177)

  • 41. Are endosomal trafficking parameters better targets for improving mAb pharmacokinetics than FcRn binding affinity?
    Gurbaxani B; Dostalek M; Gardner I
    Mol Immunol; 2013 Dec; 56(4):660-74. PubMed ID: 23917469
    [TBL] [Abstract][Full Text] [Related]  

  • 42. IL-15 and IL-2 increase Cetuximab-mediated cellular cytotoxicity against triple negative breast cancer cell lines expressing EGFR.
    Roberti MP; Barrio MM; Bravo AI; Rocca YS; Arriaga JM; Bianchini M; Mordoh J; Levy EM
    Breast Cancer Res Treat; 2011 Nov; 130(2):465-75. PubMed ID: 21308409
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The neonatal Fc receptor (FcRn) binds independently to both sites of the IgG homodimer with identical affinity.
    Abdiche YN; Yeung YA; Chaparro-Riggers J; Barman I; Strop P; Chin SM; Pham A; Bolton G; McDonough D; Lindquist K; Pons J; Rajpal A
    MAbs; 2015; 7(2):331-43. PubMed ID: 25658443
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Potentiation of tumor lysis by a bispecific antibody that binds to CA19-9 antigen and the Fc gamma receptor expressed by human large granular lymphocytes.
    de Palazzo IG; Gercel-Taylor C; Kitson J; Weiner LM
    Cancer Res; 1990 Nov; 50(22):7123-8. PubMed ID: 2146012
    [TBL] [Abstract][Full Text] [Related]  

  • 45. IgG Fc engineering to modulate antibody effector functions.
    Wang X; Mathieu M; Brezski RJ
    Protein Cell; 2018 Jan; 9(1):63-73. PubMed ID: 28986820
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The influence of antibody functional affinity on the effector functions involved in the clearance of circulating immune complexes anti-BSA IgG/BSA.
    Marzocchi-Machado CM; Polizello AC; Azzolini AE; Lucisano-Valim YM
    Immunol Invest; 1999; 28(2-3):89-101. PubMed ID: 10484684
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evaluating antibodies for their capacity to induce cell-mediated lysis of malignant B cells.
    Würflein D; Dechant M; Stockmeyer B; Tutt AL; Hu P; Repp R; Kalden JR; van de Winkel JG; Epstein AL; Valerius T; Glennie M; Gramatzki M
    Cancer Res; 1998 Jul; 58(14):3051-8. PubMed ID: 9679970
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Advances in Therapeutic Fc Engineering - Modulation of IgG-Associated Effector Functions and Serum Half-life.
    Saxena A; Wu D
    Front Immunol; 2016; 7():580. PubMed ID: 28018347
    [TBL] [Abstract][Full Text] [Related]  

  • 49. IgGA: a "cross-isotype" engineered human Fc antibody domain that displays both IgG-like and IgA-like effector functions.
    Kelton W; Mehta N; Charab W; Lee J; Lee CH; Kojima T; Kang TH; Georgiou G
    Chem Biol; 2014 Dec; 21(12):1603-9. PubMed ID: 25500223
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Tumor-associated and microbial proteases compromise host IgG effector functions by a single cleavage proximal to the hinge.
    Brezski RJ; Vafa O; Petrone D; Tam SH; Powers G; Ryan MH; Luongo JL; Oberholtzer A; Knight DM; Jordan RE
    Proc Natl Acad Sci U S A; 2009 Oct; 106(42):17864-9. PubMed ID: 19815504
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A Cell-Based Reporter Assay Measuring the Activation of Fc Gamma Receptors Induced by Therapeutic Monoclonal Antibodies.
    Aoyama M; Tada M; Ishii-Watabe A
    Methods Mol Biol; 2019; 1904():423-429. PubMed ID: 30539484
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The N-linked oligosaccharide at Fc gamma RIIIa Asn-45: an inhibitory element for high Fc gamma RIIIa binding affinity to IgG glycoforms lacking core fucosylation.
    Shibata-Koyama M; Iida S; Okazaki A; Mori K; Kitajima-Miyama K; Saitou S; Kakita S; Kanda Y; Shitara K; Kato K; Satoh M
    Glycobiology; 2009 Feb; 19(2):126-34. PubMed ID: 18952826
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antigen targeting to myeloid-specific human Fc gamma RI/CD64 triggers enhanced antibody responses in transgenic mice.
    Heijnen IA; van Vugt MJ; Fanger NA; Graziano RF; de Wit TP; Hofhuis FM; Guyre PM; Capel PJ; Verbeek JS; van de Winkel JG
    J Clin Invest; 1996 Jan; 97(2):331-8. PubMed ID: 8567952
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Maximizing the potency of an anti-TLR4 monoclonal antibody by exploiting proximity to Fcγ receptors.
    Loyau J; Malinge P; Daubeuf B; Shang L; Elson G; Kosco-Vilbois M; Fischer N; Rousseau F
    MAbs; 2014; 6(6):1621-30. PubMed ID: 25484053
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Fc-engineered EGF-R antibodies mediate improved antibody-dependent cellular cytotoxicity (ADCC) against KRAS-mutated tumor cells.
    Schlaeth M; Berger S; Derer S; Klausz K; Lohse S; Dechant M; Lazar GA; Schneider-Merck T; Peipp M; Valerius T
    Cancer Sci; 2010 May; 101(5):1080-8. PubMed ID: 20331636
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Structural characterization of GASDALIE Fc bound to the activating Fc receptor FcγRIIIa.
    Ahmed AA; Keremane SR; Vielmetter J; Bjorkman PJ
    J Struct Biol; 2016 Apr; 194(1):78-89. PubMed ID: 26850169
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Fc Engineering for Developing Therapeutic Bispecific Antibodies and Novel Scaffolds.
    Liu H; Saxena A; Sidhu SS; Wu D
    Front Immunol; 2017; 8():38. PubMed ID: 28184223
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets.
    Clynes RA; Towers TL; Presta LG; Ravetch JV
    Nat Med; 2000 Apr; 6(4):443-6. PubMed ID: 10742152
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Impact of intrinsic affinity on functional binding and biological activity of EGFR antibodies.
    Zhou Y; Goenaga AL; Harms BD; Zou H; Lou J; Conrad F; Adams GP; Schoeberl B; Nielsen UB; Marks JD
    Mol Cancer Ther; 2012 Jul; 11(7):1467-76. PubMed ID: 22564724
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Tandemly repeated Fc domain augments binding avidities of antibodies for Fcgamma receptors, resulting in enhanced antibody-dependent cellular cytotoxicity.
    Nagashima H; Tezuka T; Tsuchida W; Maeda H; Kohroki J; Masuho Y
    Mol Immunol; 2008 May; 45(10):2752-63. PubMed ID: 18353438
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.